Journal of stroke · 2026
Effect Modification by Total Bilirubin on the Association Between Hypertension and Cerebral Small Vessel Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xia Zhang, Cai Xueli, Yang Yingying, Li Shan, Wang Mengxing, Wang Xuan, Wei Tiemin, Wang Yongjun, Wang Yilong, Pan Yuesong
Аннотация
BACKGROUND AND PURPOSE: Bilirubin has potent antioxidant, anti-inflammatory, and neuroprotective effects. Herein, we investigated whether total bilirubin (TBIL) modifies the association between hypertension and cerebral small vessel disease (CSVD).
METHODS: Data were obtained from the PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events study. TBIL and direct bilirubin (DBIL) levels were assayed using fasting venous blood samples. Indirect bilirubin (IBIL) was calculated by subtracting DBIL from TBIL. TBIL was stratified as ≤17 μmol/L and >17 μmol/L based on the biological relevance of Gilbert's syndrome. Hypertension was defined as blood pressure ≥140/90 mm Hg, self-reported hypertension history, or current use of antihypertensive agents. White matter hyperintensity, lacunes, cerebral microbleeds, and enlarged perivascular spaces were evaluated using magnetic resonance imaging and used to rate CSVD burden according to the criteria proposed by Wardlaw et al. and Rothwell et al.
RESULTS: This study included 3,061 participants, with a mean age of 61.2±6.7 years and 46.5% males. After adjusting for confounders, hypertension was associated with increased odds of presence of CSVD (Wardlaw: odds ratio [OR]=1.86, 95% confidence interval [CI] 1.41-2.44, P<0.001; Rothwell: OR=1.84, 95% CI 1.43-2.38, P<0.001) and higher modified total CSVD burden (common OR: 1.85, 95% CI 1.45-2.36, P<0.001) in participants with TBIL ≤17 μmol/L but not in TBIL >17 μmol/L (P for interaction <0.05). Johnson-Neyman analyses showed cut-off concentrations of 22.3-22.4 μmol/L for effect modification by TBIL. IBIL contributed to effect modification, whereas DBIL did not.
CONCLUSIONS: Mildly elevated TBIL may modify the association between hypertension and CSVD.
METHODS: Data were obtained from the PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events study. TBIL and direct bilirubin (DBIL) levels were assayed using fasting venous blood samples. Indirect bilirubin (IBIL) was calculated by subtracting DBIL from TBIL. TBIL was stratified as ≤17 μmol/L and >17 μmol/L based on the biological relevance of Gilbert's syndrome. Hypertension was defined as blood pressure ≥140/90 mm Hg, self-reported hypertension history, or current use of antihypertensive agents. White matter hyperintensity, lacunes, cerebral microbleeds, and enlarged perivascular spaces were evaluated using magnetic resonance imaging and used to rate CSVD burden according to the criteria proposed by Wardlaw et al. and Rothwell et al.
RESULTS: This study included 3,061 participants, with a mean age of 61.2±6.7 years and 46.5% males. After adjusting for confounders, hypertension was associated with increased odds of presence of CSVD (Wardlaw: odds ratio [OR]=1.86, 95% confidence interval [CI] 1.41-2.44, P<0.001; Rothwell: OR=1.84, 95% CI 1.43-2.38, P<0.001) and higher modified total CSVD burden (common OR: 1.85, 95% CI 1.45-2.36, P<0.001) in participants with TBIL ≤17 μmol/L but not in TBIL >17 μmol/L (P for interaction <0.05). Johnson-Neyman analyses showed cut-off concentrations of 22.3-22.4 μmol/L for effect modification by TBIL. IBIL contributed to effect modification, whereas DBIL did not.
CONCLUSIONS: Mildly elevated TBIL may modify the association between hypertension and CSVD.